Description: ASC Biosciences, Inc., a biotechnology company, develops products that restore, maintain, and improve tissue function in humans. It offers Chondrofelt, a medical device to repair articular cartilage defects caused by trauma/osteoarthritis; PeriGen, a product that regenerates peritoneum following abdominal surgery to prevent surgical adhesions; ChondroGen, a product to regenerate articular cartilage and subchondral bone in patients with cartilage damage resulting from sports injury, traumatic injury, and osteoarthritis; and RhytiGen, a product that utilizes MASCs to form connective tissue when injected under the skin. The company also provides MeniGen, a product that incorporates MASCs into a matrix for use as a universal allogeneic meniscus graft; OsteoGen, a product that utilizes MASCs in polylactic acid polymers/purchased porous bone substitutes as three-dimensional scaffolds for the healing of fractures, non-union fractures, and craniofacial defects; and DermiGen, a product that utilizes MASCs to form the cell types in skin, fibroblasts in the dermis, and keratinocytes in the epidermis. ASC Biosciences, Inc. was founded in 2015 and is based in Palm Desert, California.
Home Page: www.AmericanHemp.io
2821 S Parker Road
Aurora,
CO
80014
United States
Phone:
720 436 1394
Officers
| Name | Title |
|---|---|
| Mr. S. Mark Spoone | Pres, CEO & Director |
| Mr. Neville Pearson FCCA | Founder & Interim CFO |
| Dr. Christopher William Gilluly | Co-Founder, Sec. and Director |
Exchange: PINK
Country: US : United States of America
Currency: US Dollar ($)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Biotechnology |
| GIC Sub-Industry: | Biotechnology |
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 0.7604 |
| Price-to-Sales TTM: | 0 |
| IPO Date: | |
| Fiscal Year End: | April |
| Full Time Employees: | 0 |